TLDR
- After Roche’s Phase 3 giredestrant trial failed to reach its primary endpoint, Olema Pharmaceuticals (OLMA) dropped 41% on Monday.
- Roche’s persevERA study found no statistically significant improvement in progression-free survival.
- Roche stock declined by as much as 7.5% on this news.
- Olema’s own drug, palazestrant, is still in Phase 3 trials, and results are not expected until 2028.
- Stifel analysts stated that the sell-off could be a buying opportunity for those who believe in palazestrant’s potential.
On Monday, Olema Pharmaceuticals (OLMA) plummeted significantly after Roche reported that a late-stage breast cancer drug trial had failed. The drop was substantial — 41% — despite Olema having a completely separate drug program.
Roche’s Phase 3 persevERA study tested giredestrant combined with palbociclib against an aromatase inhibitor plus palbociclib. The trial did not achieve its primary endpoint of a statistically significant improvement in progression-free survival.
Roche said a numerical improvement was observed in the trial. However, it was not sufficient to reach statistical significance — the threshold needed to declare a drug effective in a clinical trial.
Roche stock dropped by as much as 7.5% on the news. That was the stock’s worst single-day decline in over 11 months.
The market reaction extended to because the two companies are operating in the same area — first-line metastatic breast cancer. Investors associated the Roche failure with Olema’s prospects, even though the drugs are different.
Olema is developing palazestrant, an oral selective estrogen receptor degrader (SERD). The drug is in multiple Phase 3 trials targeting breast cancer.
The most closely watched study, OPERA-02, is testing palazestrant in first-line metastatic breast cancer. Results from that study are not expected until 2028.
What Stifel Said
Stifel analysts opposed the sell-off. They noted that while the Roche outcome is not ideal for OLMA in the short term, the numerical improvement Roche saw allows for palazestrant to be a clinical differentiator.
Stifel pointed to palazestrant’s superior antagonism and pharmacokinetic profile as reasons the drug could perform better than giredestrant in the same situation.
The firm suggested that investors who believe in palazestrant’s best-in-class potential “might view today’s sell-off as a buying opportunity.” The reasoning: if giredestrant cannot succeed, the way is open for palazestrant to be the first major player in the first-line metastatic breast cancer space.
The Setup for OLMA
Palazestrant has demonstrated early promise in Phase 1 and Phase 2 data. The company has emphasized the drug as a potential best-in-class SERD, arguing that its pharmacokinetics distinguish it from competitors.
The OPERA-02 trial will be the definitive test. But that result is still approximately two years away, leaving a great deal of uncertainty in the near term.
Giredestrant failing to reach statistical significance does not automatically mean palazestrant will be successful. The two drugs work differently, and the persevERA data does not predict OPERA-02 outcomes.
OLMA stock was down 41% in Monday trading, with the stock responding to the broader negative sentiment in the oral SERD space following the Roche announcement.
